Education
About Us
Working with TipRanks
Follow Us
Hookipa Pharma (HOOK)
:HOOK
HOOK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.72 - $10.50
Previous CloseN/A
Volume38.61K
Average Volume (3M)43.67K
Market Cap
$9.04M
Enterprise Value-$14.68M
Total Cash (Recent Filing)-$61.36M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.61
Next Earnings
May 08, 2025EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding9,659,522
10 Day Avg. Volume26,951
30 Day Avg. Volume43,670
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.34
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.34
Forecast
1Y Price Target
$2.00Price Target Upside166.67% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Hookipa Pharma News
PremiumCompany Announcements
Hookipa Pharma Seeks Validation for Stockholder Meetings
---
Bulls Say, Bears Say
Bulls Say
Cash Flow ManagementEnding the quarter with cash of $60M would fund the company beyond 2025 based on the model.
Clinical Trial ResultsThe combination of eseba-vec and Keytruda continues to show beneficial responses in first-line head-and-neck cancer, supporting a Market Outperform rating for Hookipa Pharma.
Bears Say
Financial PerformanceHookipa had approximately $60M in cash, which is believed to be insufficient to support the company to realize meaningful value inflection points from its own pipeline.
Merger UncertaintyAll discussions regarding the merger with Poolbeg have been non-binding and non-exclusive, increasing uncertainty about Hookipa’s future path.
Shareholder DilutionCurrent Hookipa shareholders are expected to face significant dilution.
---
Ownership Overview
3.49% Insiders
5.22% Mutual Funds
39.50% Other Institutional Investors
48.45% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOOK FAQ
What was Hookipa Pharma’s price range in the past 12 months?
Hookipa Pharma lowest stock price was $0.72 and its highest was $10.50 in the past 12 months.
What is Hookipa Pharma’s market cap?
Hookipa Pharma’s market cap is $9.04M.
When is Hookipa Pharma’s upcoming earnings report date?
Hookipa Pharma’s upcoming earnings report date is May 08, 2025 which is in 15 days.
How were Hookipa Pharma’s earnings last quarter?
Hookipa Pharma released its earnings results on Mar 20, 2025. The company reported -$1.95 earnings per share for the quarter, missing the consensus estimate of -$1.123 by -$0.827.
Is Hookipa Pharma overvalued?
According to Wall Street analysts Hookipa Pharma’s price is currently Undervalued.
Does Hookipa Pharma pay dividends?
Hookipa Pharma does not currently pay dividends.
What is Hookipa Pharma’s EPS estimate?
Hookipa Pharma’s EPS estimate is -1.04.
How many shares outstanding does Hookipa Pharma have?
Hookipa Pharma has 9,659,522 shares outstanding.
What happened to Hookipa Pharma’s price movement after its last earnings report?
Hookipa Pharma reported an EPS of -$1.95 in its last earnings report, missing expectations of -$1.123. Following the earnings report the stock price went up 0.82%.
Which hedge fund is a major shareholder of Hookipa Pharma?
Currently, no hedge funds are holding shares in HOOK
---
Company Description
Hookipa Pharma
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
---
HOOK Stock 12 Month Forecast
Average Price Target
$2.00
▲(166.67% Upside)
Technical Analysis
Best Analysts Covering HOOK
1 Year
1 Year Success Rate
1/22 ratings generated profit
1 Year Average Return
-59.82%
reiterated a buy rating 9 months ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 4.55% of your transactions generating a profit, with an average return of -59.82% per trade.
---